Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma
Prospective trial shows high efficacy and manageable safety of ORT therapy in untreated PCNSL patients, indicating viability for elderly with MCD subtypes.
Key Points
The regimen achieved a high objective response rate of 86.2% in the patient cohort.
Next-generation sequencing revealed TP53 mutations in 13.6% of patients, indicating genetic variations in PCNSL.
Adverse events were primarily grade 1-2, highlighting manageable safety in the treatment regimen.
Multicenter analysis suggests potential effectiveness among older patients, specifically those with MCD subtypes.